THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE

Ревматоидный артрит (РА) является наиболее частым и тяжелым хроническим воспалительным заболеванием суставов, приводящим к ранней инвалидизации и сокращению продолжительности жизни пациентов. В ряде работ продемонстрировано, что краткосрочный и долгосрочный прогноз заболевания гораздо более благоприятен при достижении ремиссии на ранних стадиях болезни, однако эффективность того или иного лекарственного препарата широко варьирует у разных пациентов, что связано с гетерогенностью самого заболевания и рядом других причин. В связи с этим по-прежнему актуальной остается проблема поиска биомаркеров, позволяющих осуществлять персонифицированный выбор схемы лечения в каждом конкретном случае. Одним из эффективных и безопасных препаратов, применяемых в терапии РА, является ритуксимаб (РТМ), представляющий собой химерные моноклональные антитела к мембранному CD20 антигену В-клеток, вызывающие деплецию различных субпопуляций В-лимфоцитов. По сравнению с другими генно-инженерными биологическими препаратами, РТМ отличается длительной эффективностью одного курса терапии, сохраняющейся в течение 6 мес и более. В настоящее время в литературе представлено большое количество данных, посвященных роли клеточных и молекулярных биомаркеров в прогнозировании эффективности терапии РТМ при РА, часть из которых рассмотрены в данном обзоре. Ключевые слова: ревматоидный артрит; активность заболевания; ритуксимаб; эффективность терапии; клеточные и молекулярные биомаркеры. Для ссылки: Авдеева АС, Кусевич ДА. Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные). Научно-практическая ревматология. 2017;55(3):295-303.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.14412/1995-4484-2017-295-303
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Ревматоидный артрит в реальной клинической практике: инициация терапии генно-инженерными биологическими препаратами. Результаты проекта «Компьютерные терминалы самооценки для пациентов с ревматическими заболеваниями» («ТЕРМИНАЛ-И»)

  2019cited by this paper
• Опыт использования автоматической информационной системы для составления клинических ситуационных задач в процессе преподавания дисциплины "Клиническая лабораторная диагностика"

  2017cited by this paper
• Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability.

  2016cited by this paper
• A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients

  2016cited by this paper
• A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

  2016cited by this paper
• Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

  2016cited by this paper
• Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  2016cited by this paper
• Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis.

  2016cited by this paper
• MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.

  2015cited by this paper
• Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

  2015cited by this paper
• IL-33 Exacerbates Periodontal Disease through Induction of RANKL

  2015cited by this paper
• Usefulness of monitoring of B cell depletion in rituximab‐treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study

  2015cited by this paper
• Targeting IL-33 in Autoimmunity and Inflammation

  2015cited by this paper
• ИММУНОЛОГИЧЕСКИЕ ПРЕДИКТОРЫ ЭФФЕКТА АНТИ-В-КЛЕТОЧНОЙ ТЕРАПИИ ПРИ РЕВМАТОИДНОМ АРТРИТЕ

  2014cited by this paper
• Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial

  2014cited by this paper
• From Synovial Tissue to Peripheral Blood: Myeloid Related Protein 8/14 Is a Sensitive Biomarker for Effective Treatment in Early Drug Development in Patients with Rheumatoid Arthritis

  2014cited by this paper
• The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study

  2013influential reference
• THU0167 MRP8/14 Serum Complexes as Predictor of Response to Biological Treatments in Rheumatoid Arthritis

  2013cited by this paper
• Alarmins in tendinopathy: unravelling new mechanisms in a common disease.

  2013cited by this paper
• Regulation of type I interferon responses

  2013cited by this paper
• Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.

  2013cited by this paper
• Predictive Factors of Rituximab Response in Rheumatoid Arthritis: Results From a French University Hospital

  2013cited by this paper
• Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients

  2012cited by this paper
• Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis.

  2012cited by this paper
• B lymphocyte-typing for prediction of clinical response to rituximab

  2012cited by this paper
• TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis.

  2012cited by this paper
• Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study

  2012cited by this paper
• Клинико-иммунологические эффекты анти-В-клеточной терапии у больных ревматоидным артритом

  2012cited by this paper
• The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

  2012cited by this paper
• Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

  2012influential reference
• Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

  2012cited by this paper
• IL-33 regulates TNF-α dependent effects in synovial fibroblasts

  2012cited by this paper
• Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis

  2012cited by this paper
• IL-33 Activates B1 Cells and Exacerbates Contact Sensitivity

  2011cited by this paper
• Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.

  2011cited by this paper
• Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

  2011cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• Disease-associated functions of IL-33: the new kid in the IL-1 family

  2010cited by this paper
• Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.

  2010cited by this paper
• Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab

  2010cited by this paper
• Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

  2010cited by this paper
• Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.

  2010cited by this paper
• Biomarkers predictors of good EULAR response to B cell depletion therapy (BCDT) in seropositive Rheumatoid Arthritis patients

  2010cited by this paper
• The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells

  2010cited by this paper
• Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

  2010cited by this paper
• Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

  2010cited by this paper
• B cells and immunological tolerance.

  2009cited by this paper
• Protein biochip array technology to monitor rituximab in rheumatoid arthritis

  2009cited by this paper
• Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis

  2009cited by this paper
• Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis

  2009cited by this paper
• Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

  2008cited by this paper
• [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].

  2008cited by this paper
• Cytokine-producing B lymphocytes-key regulators of immunity.

  2008cited by this paper
• Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients

  2007cited by this paper
• Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis

  2007cited by this paper
• Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

  2007cited by this paper
• Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis

  2006cited by this paper
• Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis

  2005cited by this paper
• IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.

  2005cited by this paper
• Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells.

  2005cited by this paper
• Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis Refractory to Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor- α Treatment

  2005cited by this paper
• Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

  2004cited by this paper
• MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes.

  2004cited by this paper
• COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.

  2002cited by this paper
• Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid.

  2002cited by this paper
• The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils.

  1998cited by this paper
• Extended Report

  year unknowncited by this paper

• [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].

  2022cites this paper